Ipsen Sa

Ipsen S.A. - Information relating to the holding of the Combined Shareholders’ Meeting of 13 May 2026

Ojemda® approved in the European Union as the first targeted therapy in relapsed or refractory pediatric low-grade glioma regardless of BRAF alteration

Ipsen announces that Beech Tree has obtained an exemption from the obligation to submit a public tender offer

Ipsen announces the availability of its 2025 Universal Registration Document

Ipsen showcases transformative potential of early immuno-oncology pipeline at AACR